Scientific Publications Archive: Plazomicin
Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study
Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study
Plazomicin Versus Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results from the Phase 3 EPIC Study
Assessment of the In Vivo Efficacy of PLZ Alone or in Combination with MEM or TGC against EB Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent (I+) Murine Septicemia Model
Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing
Plazomicin (PLZ) Associated with Improved Survival and Safety Compared to Colistin (CST) in Serious Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study
Evaluating Once-Daily Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Results from a Phase 3 Study (EPIC)
Aminoglycoside-Resistant Genes among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011-2015: CANWARD Surveillance Study
Investigating the Post-Antibiotic Effect of Plazomicin against Multidrug Resistant Enterobacteriaceae
In Vitro Activity of Plazomicin and Comparator Agents against Urinary Tract Infection Isolates from the United States and Europe
Antimicrobial Activity of Plazomicin against Enterobacteriaceae Producing Carbapenemases from 50 Brazilian Medical Centers
The Pharmacodynamics (PD) of Plazomicin (PLZ) and Amikacin (AMK) against Enterobacteriaceae Studied in an In Vitro Pharmacokinetic (PK) Model of Infection
In Vitro Activity of Plazomicin (PLZ) and Comparators against Facultative Anaerobes Incubated Aerobically and Anaerobically and Obligate Anaerobes
Impact of Changes in Growth Medium, Inoculum Density and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin
In vitro Activity of Plazomicin and Underlying Resistance Mechanisms in Enterobacteriaceae Isolated from Blood Isolates from Hospitalized Patients in Turkey (Abstract #2614)
Plazomicin Activity Against European Enterobacteriaceae Isolates Carrying Aminoglycoside-Modifying Enzymes and 16S rRNA Methylases (Abstract #3611)
Activity of Plazomicin and Comparator Agents Tested Against Recent Clinical Isolates Collected in the Asia-Pacific Region, Europe and Latin America (Abstract #3596)
In vitro Activity of Plazomicin Against Colistin-Resistant Enterobacteriaceae Including Plasmid-Encoded MCR-1-Producing Isolates (Abstract #1156)
Nationwide Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae Isolates from Greek Hospitals, in Regards to Plazomicin and Aminoglycoside Resistance (Abstract #1600)
Plazomicin Associated with Improved Survival and Safety Compared to Colistin in Serious Carbapenem-Resistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study
Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract infection (cUTI) and Acute Pyelonephritis (AP): Results of the EPIC Study
Activity of Plazomicin and Comparator Agents Tested Against Gram-negative and -positive Clinical Isolates Collected in USA Hospitals During 2015
Population Pharmacokinetics (PPK) of Plazomicin and Use of Therapeutic Drug Management (TDM) in Critically Ill Patients
Utility of Therapeutic Drug Management (TDM) in Managing Plazomicin Pharmacokinetic (PK) Variability in Patients with Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE)
In Vitro Activity of Plazomicin Against 110 Carbapenemase-producing Enterobacteriaceae Clinical Isolates
An Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug Resistant Enterobacteriaceae
Activity of Plazomicin in Combination with Other Antibiotics Against Multidrug Resistant Enterobacteriaceae
In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae
Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?
Plazomicin Activity Against Carbapenem Non-susceptible Enterobacter Strains that Exhibit Various Levels of Resistance to Aminoglycosides
In vitro Activity of Ceftazidime-avibactam, Ceftolozane-tazobactam, and Plazomicin against Carbapenem-resistant Pseudomonas aeruginosa
Plazomicin has potent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates carrying different aminoglycoside-modifying enzymes
Baseline Pathogens and Patient Outcomes in a Phase 2 Study Comparing Plazomicin (ACHN-490) to Levofloxacin in Complicated Urinary Tract Infection (cUTI) including Acute Pyelonephritis (AP)
In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp.
Diversity of aminoglycoside modifying enzymes among carbapenem-resistant Klebsiella pneumoniae isolates and their impact on activity of old- and next-generation aminoglycosides
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
In Vitro Activity of Plazomicin and Comparators Against Carbapenemase - Producing Enterobacteriaceae Clinical Isolates
Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model.